Drug intelligence / Profile preview

PSY-06

Development stage: Preclinical
Lead developer: Psy Therapeutics
Modality: Small Molecules

Overview

PSY-06 is a preclinical-stage therapeutic candidate being developed by Psy Therapeutics for the treatment of anxious depression. The drug was identified through the company's proprietary Psy-Finder platform, which screens for compounds that can restore synaptic health and promote neurogenesis in human-derived neuronal models. Although the specific molecular target and modality have not been explicitly detailed in public pipeline disclosures, Psy Therapeutics focuses on the development of small molecule modulators for neuropsychiatric conditions where traditional therapies, such as SSRIs, are often insufficient. The program is currently in the preclinical phase of development, aiming to address the high unmet need in patients suffering from comorbid anxiety and depressive symptoms.

Other names: PSY-06PSY06PSY 06

Beyond the preview

Go deeper on PSY-06.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PSY-06.

Explore the full profile